Explore more price target data and ratings for Medpace Holdings, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Medpace Holdings, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This…
What Happened? Shares of clinical research company Medpace Holdings NASDAQ:MEDPjumped 14.4% in the afternoon session after the company reported second-quarter financial results that exceeded Wall Street's expectations. GAAP earnings per share came in at $4.25, surpassing analyst estimates of $3.99…
Q2 2026 delivered strong revenue and net income growth, driven by record net bookings, a surge in oncology awards, and improved business conditions. Guidance for 2026 was raised, with robust cash flow and significant share repurchases supporting capital allocation.Based on Medpace Holdings, Inc. [M…
Medpace Holdings reported second-quarter 2026 results with revenue of $707.3 million, up 17.2% year-over-year, and GAAP net income of $121.4 million, or $4.25 per diluted share. EBITDA for the quarter was $153.4 million (21.7% margin) and net new business awards totaled $795.7 million, producing a…
Q2 2026 saw revenue rise 17.2% year-over-year to $707.3 million, with net income up to $121.4 million and EBITDA margin steady at 21.7%. Full-year 2026 guidance projects up to 14% revenue growth and EPS between $17.25 and $17.95.Original document: Medpace Holdings, Inc. [MEDP] SEC 8-K Current Repor…
(09:59 GMT) Medpace Holdings Price Target Raised to $515.00/Share From $490.00 by Jefferies
